Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. - Wikidata - awgldk - TriplyDB

Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma.

Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma.

http://www.wikidata.org/entity/Q44932116

about

Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective Discrepant alterations in main candidate genes among multiple primary melanomas Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.Variation of mutant allele frequency in NRAS Q61 mutated melanomas.Pharmacogenomics: Current State-of-the-Art Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.Comparison of Melanoma Subtypes among Korean Patients by Morphologic Features and Ultraviolet Exposure.Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps.The clinical response to vemurafenib in a patient with a rare BRAFV600DK601del mutation-positive melanoma.Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site.Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma Genotyping of cutaneous melanoma.Update on Molecular Pathology of Cutaneous Melanocytic Lesions: What is New in Diagnosis and Molecular Testing for Treatment?Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma Molecular and immunohistochemical characterization reveals novel BRAF mutations in metanephric adenoma Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells.Variations of BRAF mutant allele percentage in melanomas Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma BRAFV600E immunopositive melanomas show low frequency of heterogeneity and association with epithelioid tumor cells: a STROBE-compliant article.Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.Tumor cellularity as a quality assurance measure for accurate clinical detection of BRAF mutations in melanoma.A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report MAP Kinase Pathways: Molecular Roads to Primary Acral Lentiginous Melanoma JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma Which melanoma patient carries a BRAF-mutation? A comparison of predictive models.Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma NRAS and EPHB6 mutation rates differ in metastatic melanomas of patients in the North Island versus South Island of New Zealand.Genetic alterations and personalized medicine in melanoma: progress and future prospects.The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation.Primary melanocytic tumors of the central nervous system: a review with focus on molecular aspects.BRAF and MEK inhibition in melanoma.Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma.Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease.A Sensitive Peptide Nucleic Acid Probe Assay for Detection of BRAF V600 Mutations in Melanoma.Targeted agents and immunotherapies: optimizing outcomes in melanoma.Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma.

P2860

Q26770492-349EB9DB-67AF-46D4-8729-D61200C913B7 Q28070038-92FDFD0F-0063-4A58-A0F8-99F4FC52AB26 Q30578299-99AEF87F-280F-4258-BD87-58A872585049 Q33413244-DB47F088-1FB7-47E2-A831-B6CA90E153BB Q33862539-7790F50E-BA74-4ED5-8094-92F618707795 Q33891714-BBF0ACDE-3A28-438D-9622-01BC34A138D9 Q33918101-4F8416CA-4DF5-407B-87CF-56C3DADFC436 Q34054383-D3DE9EB2-C352-4B6C-84F4-F5F7F7E327A7 Q34163458-5ABF239A-7821-4C4A-A1D0-FDE1ED8F863E Q34316552-0DDC01BA-BC2E-40EA-8E6C-613C40798EEA Q34446657-FCC19394-20CC-450B-8063-83338B132016 Q34662717-8A77018A-BD37-4D5E-8E83-C1C24E40A6D1 Q34667738-E4D812F5-A629-417C-B1BD-234B427AF688 Q34928118-E5A18098-F8C2-4DFE-AECF-3383942C0ACF Q35063621-339F0684-09CC-4044-A250-B63B1E3E0F57 Q35141834-D774869E-C5F4-40D9-BFFB-01994FE98B2F Q35177372-8D8E859A-4AB1-4A23-9CD5-0D97B2B7E54D Q35550099-8EF0A032-CAAF-42A7-A2B8-C546EF176996 Q35682567-17B4ED12-6F59-4430-B2EC-194D1B414133 Q35798726-4D12D5A9-F0DC-404B-B27C-B760764EDF92 Q35889462-73EBF4CA-AB9C-42B1-BE3D-7E42063E2875 Q36154050-42749164-891F-47EA-BC3E-2C8814B355C0 Q36260662-C4261068-B0AD-4EAE-9539-291B1E7C33D7 Q36276146-A080027A-EB50-4527-B8B2-8E10BFDC8167 Q36764374-5A4CBF99-79D2-4502-8140-5B68EF474916 Q36960097-E6AA46F4-6E2B-4C86-9551-C55FA360CD7E Q36973484-F66ED2E3-465C-45A1-B82E-F8D3745CB88B Q37233445-49364546-AED8-49E3-B0C4-C8735F9A8C0A Q37392661-2D764B4C-0F63-44B8-8180-E2B0097C6F05 Q37514256-6885D985-9BE2-4CA2-BBB0-F4698AFDF36C Q37520141-DA5F25D6-B542-424F-9979-A22141D955E0 Q38186704-C2E098F6-D69C-4124-8F76-5AD9F8D31DF5 Q38203019-367D38BC-29A7-4792-88D6-2B7E7F4913B8 Q38297995-3282D943-3095-4FAF-A445-1316BCA11205 Q38342905-2B9731B0-8F7C-44C1-BD85-6159E5CB999A Q38689912-E75AFEC9-F219-4B2C-8718-D06792C2AEDE Q38700671-AA738CA4-3A5B-409B-BA59-A4764BCDFA6B Q38749766-4645A598-0433-4BE1-BD5A-8AAE8B482490 Q38856722-CB9FD0E5-92D0-497D-BF58-FD3068835B85 Q39077390-9684130E-BCBE-456D-8E58-F5CACDA1BE5E

P2860

Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma.

http://www.wikidata.org/entity/Q44932116

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Frequency and spectrum of BRAF ...... udy of 1112 cases of melanoma.

@en

Frequency and spectrum of BRAF ...... udy of 1112 cases of melanoma.

@nl

type

label

Frequency and spectrum of BRAF ...... udy of 1112 cases of melanoma.

@en

Frequency and spectrum of BRAF ...... udy of 1112 cases of melanoma.

@nl

prefLabel

Frequency and spectrum of BRAF ...... udy of 1112 cases of melanoma.

@en

Frequency and spectrum of BRAF ...... udy of 1112 cases of melanoma.

@nl

P1433

Q44932116-02B27601-074B-4194-B869-EB4D46BD8FA7

P1476

Q44932116-648D398D-2220-4D06-9AF4-46A631F71A4E

P2093

Q44932116-3313F926-F568-45A2-A16C-A7485EBABB78

Q44932116-3C0EC167-0B42-4D60-84BC-969D2C357D08

Q44932116-4FBC610D-4441-4257-A3AF-51E7AAF57614

Q44932116-71199C77-8AE2-4B0E-988B-DB42BBF16236

Q44932116-77B5C5CC-01AA-4CED-B05A-32D4FE1D59E0

Q44932116-8D99DBB8-9D0A-43F8-90CB-D4D390E9B5A1

Q44932116-C4472EBC-F74F-489F-9240-501BC4CD84A1

Q44932116-CD0F2CEA-DD2D-4B15-B69B-7EB2D17AF1C1

Q44932116-E5248B90-EA58-4B2D-80D0-03169EE06551

Q44932116-F32B8E51-CDC2-4F70-8AA7-D4FBC2FC77F6

P2860

Q44932116-01B963A2-53C2-4C85-AD1E-48EE7ABA89F9

Q44932116-07A9742A-E91E-4DAF-AE61-F538676B82A3

Q44932116-0D6D002A-9887-4EC7-AC9D-D6301A5574E4

Q44932116-226ABE0B-AF37-4EC2-A0A2-7A248279A21A

Q44932116-23642C1B-CA5C-4BBA-A03B-985766332ADC

Q44932116-249882B0-59A4-4F20-805E-911F9372BA18

Q44932116-28DFD482-C249-451A-897C-3606B389B404

Q44932116-2DABD988-3363-45BD-867E-2E64B73D5000

Q44932116-2F3D3739-B4DA-420A-96E7-9D4A7639D319

Q44932116-40B5516B-094A-4C3E-A31B-1DE13A7DA133

P304

Q44932116-CC87FDE4-2E76-436A-84F3-34B2AE241D78

P31

Q44932116-F740B321-1FC9-470E-A3FD-B978946E7CB0

P356

Q44932116-A322D17D-4312-4E33-AB5D-F2634C3C85E8

P433

Q44932116-53266EF3-BF68-4EF1-9442-7AF20F345D2E

P478

Q44932116-6172EF32-5855-4579-AC26-5BA28A7FCC28

P50

Q44932116-61E13308-4A25-4ED3-A1BD-91BB01124A18

P577

Q44932116-76AF351D-7619-4F2B-844F-F70803D4E3D3

P5875

Q44932116-E9DE9969-07C5-4B61-B775-3721B0C51211

P698

Q44932116-64488553-ABB8-40E4-A471-E697071468E3

P932

Q44932116-1570D2A2-D3E3-4CCF-885D-AF6EF7257DF3

P356

J.JMOLDX.2012.10.002

P1433

The Journal of Molecular Diagnostics

P1476

Frequency and spectrum of BRAF ...... udy of 1112 cases of melanoma.

@en

P2093

Bedia A Barkoh

http://www.w3.org/2001/XMLSchema#string

Hui Yao

http://www.w3.org/2001/XMLSchema#string

John M Galbincea

http://www.w3.org/2001/XMLSchema#string

Kenneth D Aldape

http://www.w3.org/2001/XMLSchema#string

Keyur P Patel

http://www.w3.org/2001/XMLSchema#string

L Jeffrey Medeiros

http://www.w3.org/2001/XMLSchema#string

Michael A Davies

http://www.w3.org/2001/XMLSchema#string

Rajyalakshmi Luthra

http://www.w3.org/2001/XMLSchema#string

Shalini Verma

http://www.w3.org/2001/XMLSchema#string

Wesley O Greaves

http://www.w3.org/2001/XMLSchema#string

P2860

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.

NRAS mutation status is an independent prognostic factor in metastatic melanoma.

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Mutations of the BRAF gene in human cancer

Determinants of BRAF mutations in primary melanomas

Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay.

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.

Somatic activation of KIT in distinct subtypes of melanoma.

P304

220-226

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JMOLDX.2012.10.002

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Alexander J. Lazar

P577

2012-12-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234010273

http://www.w3.org/2001/XMLSchema#string

P698

23273605

http://www.w3.org/2001/XMLSchema#string

P932

5707183

http://www.w3.org/2001/XMLSchema#string